(HOMA-IR), were determined and compared for all groups. The usefulness of the studied serum biomarkers for predicting liver fibrosis was evaluated using a receiver operating characteristic curve. Results: Serum levels of STAT5 were significantly lower in patients compared to controls (9.69 ± 5.62 vs. 14.73 ± 6.52, p ≤ 0.001); on the contrary, TGF-β 1 , α-SMA, and HOMA-IR were significantly higher in patients compared to controls (mean: 1,796.04 vs. 1,636.94; 14.94 vs. 8.1; and 7.91 vs. 4.18; p ≤ 0.01 and 0.001, respectively). TGF-β 1 and α-SMA showed a progressive increase with advancing severity of hepatic fibrosis (mean TGF-β 1 : 2,058.4 in F1-F2 and 1,583.8 in F3-F4, p ≤ 0.04; mean α-SMA: 13 .59 in F1-F2 and 16.62 in F3-F4, p ≤ 0.05). STAT5 had a significant negative correlation with TGF-β 1 (p ≤ 0.001), while no correlation was detected with α-SMA (p ≤ 0.8). Conclusions: STAT5 may play a significant role in hepatic fibrogenesis through the induction of TGF-β 1 but not through the activation of hepatic stellate cells.
Introduction
Hepatitis C virus (HCV) is a major cause of chronic liver diseases including steatosis, cirrhosis, fibrosis, and hepatocellular carcinoma [1] . Hepatic fibrosis develops primarily as a consequence of chronic viral hepatitis [2] . The mechanism of hepatic fibrosis is not fully understood. In response to liver injury, many inflammatory cytokines such as interleukin (IL)-6, interferon (IFN)-γ, IFN-α/β, and IL-22 are produced by different liver cells and play roles in regulating liver fibrogenesis [3] . Many of these cytokines can activate the Janus kinase/signal transducer and activator of transcription (JAK-STAT) signaling pathway through binding to its corresponding transmembrane receptor complex [4] . STAT5 is activated mainly in hepatocytes by growth hormone (GH) [5] . Several physiological processes are regulated by GH-STAT5 signaling through expression of target genes. Alteration of STAT5 signaling is associated with liver conditions such as fatty liver, fibrosis, and hepatocellular carcinoma [6] . Hepatocyte and cholangiocyte deletion of STAT5 in animal studies has revealed early and severe liver fibrosis through a reduced expression of important hepato-protective genes as well as increased numbers of apoptotic hepatocytes [7] . Loss of hepatic GH-STAT5 signaling causes defects in lipid and glucose metabolism leading to steatosis, hyperglycemia, and insulin resistance. TGF-β 1 is secreted from HSC and Kupffer cells, but with inflammation hepatocytes gradually become the major source of TGF-β 1 [8] [9] [10] [11] ; it is the most important cytokine that stimulates the production of extracellular matrix (ECM) by HSC [12] and can induce apoptosis in hepatocytes, leading to cirrhosis [13] .
Hepatic stellate cells (HSC) are the primary producers of connective tissue in response to liver injury. Chronic liver injury, however, leads to the persistent activation of HSC, accumulation of ECM and the eventual development of hepatic fibrosis [14] . Activation of HSC is induced by paracrine stimulation of the surrounding cells in the liver, such as hepatocytes, Kupffer cells, endothelial cells, leukocytes, and platelets, and the stimuli include cytokines, lipid peroxides, growth factors, and reactive oxygen species [15] . Activated HSC lose lipid droplets stored in the cytoplasm, proliferate, and gain an abundance of microfilaments that consist mainly of α-smooth muscle actin (α-SMA). Hence, α-SMA is established as a reliable marker of activated HSC, although these cells express other markers as well [16] .
Although the functions of hepatocyte STAT5 have been extensively investigated in animal models, little is known about STAT5 in human studies. Therefore, the objective of this study was to test whether STAT5 has a role in the pathogenesis of liver fibrogenesis in patients with chronic hepatitis C (CHC) and if it has any relationship to TGF-β 1 and α-SMA as well as to metabolic factors such as lipid and insulin resistance.
Subjects and Methods
Due to the rarity of similar previous studies, it was difficult to calculate the sample size via the usual methods. Therefore, during the study period all eligible cases were included. Sixty-five naive patients with compensated CHC who attended the Liver Unit at Minia University Hospital, El Minia, Egypt, were included in this study.
The Institutional Review Board approved this study. Written informed consent was obtained from each participant. This study was conducted from February 2015 to January 2016 in accordance with the ethical guidelines of the Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice. The target population included patients with CHC suffering different grades of fibrosis. Grades of hepatic fibrosis were estimated using Fibroscan (transient elastography). Accordingly, the patients were classified into 4 groups based on the breakpoints in relation to the METAVIR score [17] (F0-F1: 2.5-7, F2: 7-9.5, F3: 9.5-12.5, and F4: > 12.5) according to transient elastography. The inclusion criteria were: age ≥18 years, CHC infection based on the presence of anti-HCV antibodies, and detectable serum HCV-RNA for > 6 months. The exclusion criteria were: diabetes mellitus diagnosed according to American Diabetes Association classification criteria and other causes of liver disease including concomitant hepatitis B virus infection, human immunodeficiency virus, Schistosoma infection, autoimmune hepatitis, and an alcohol intake > 40 g/day in the last 6 months prior to the start of antiviral treatment. Twenty healthy persons (10 males and 10 females, age 20-60 years) from among the medical and paramedical staff working in the same hospital volunteered to participate in this study as control subjects.
Clinical Assessment
All of the participants underwent a full history taking and a thorough clinical examination with a special emphasis on age, gender, and route of HCV transmission. Weight (kg) and the height (m) were measured and the BMI calculated as weight divided by the square of the height (kg/m 2 ). Waist circumference was measured 1 inch above the navel or midpoint between the lower margin of the last palpable rib and the top of the iliac crest parallel to the floor, while the hip circumference was measured at the widest part of the buttocks or hip parallel to the floor and the waist/hip ratio was calculated.
Laboratory Assessment
Venous blood was drawn after a 12-h overnight fast to determine the serum levels of hemoglobin, white blood cells, platelet count, bilirubin, alanine aminotransferase, aspartate aminotransferase, albumin, prothrombin time, international normalized ratio, total cholesterol, HDL, LDL cholesterol, triglycerides, glucose, insulin, STAT5, α-SMA, TGF-β 1 and serum glucose, alanine aminotransferase, aspartate aminotransferase, total and HDL cholesterol, and triglycerides were determined by automated procedures. Electrochemiluminescence immunoassay (Roche Diagnostics, Indianapolis, IN, USA) was used to determine serum insulin levels. Insulin resistance was then calculated in all patients by homeostasis model assessment of insulin resistance (HOMA-IR) using the standard formula (HOMA-IR = fasting insulin [μIU/mL] × fasting glucose [mmol/L]/22.5). Serum STAT5, α-SMA, and TGF-β 1 were measured using an enzyme-linked immunosorbent assay (Quantikine ELISA; R&D Systems, Minneapolis, MN, USA).
Statistical Analysis
The collected data were coded, tabulated, and statistically analyzed using Statistical Package for Social Sciences (SPSS) software version 20 (SPSS Inc., Chicago, IL, USA). Descriptive statistics were done and the results are reported as means, SD, and ranges for parametric quantitative data and as numbers and percentages for categorical data. Analyses were done for parametric quantitative data between 2 groups using an independent-samples t test, and for nonparametric quantitative data the Mann-Whitney test was used. Analyses were done for qualitative data using the χ 2 test (if the number per cell was more than 5) and the Fisher exact test (if the number per cell was < 5). Correlations between 2 quantitative variables were determined using the Pearson correlation coefficient and for qualitative ordinal variables they were evaluated using the nonparametric Spearman ρ correlation coefficient. The receiver operating characteristic curve was done to determine the cutoff point, the area under the curve (AUC), and the sensitivity and specificity of the studied serum biomarkers for predicting severe fibrosis. The level of significance was taken as p ≤ 0.05. Table 1 presents the demographic and base line characteristics of CHC patients. The mean age was 46.4 ± 12.4 years (range 20-67 years); the male/female ratio was 46/19. The mean BMI was 22.28 ± 1.9 (range 22-34). Based on the Fibroscan examination, 36 patients had mild fibrosis (F1, n = 15; F2, n = 21), while 29 patients had moderate to severe fibrosis (F3, n = 13; F4, n = 16). Table 2 presents the levels of the metabolic factors, lipid profile, STAT5, TGF-β 1 , and α-SMA in CHC patients compared to controls. The levels of HOMA-IR, TGF-β 1 , and α-SMA were significantly higher in patients compared to Values are presented as means ± SD (range) unless otherwise stated. The total number of patients was 65. ALT, alanine transaminase; AST, aspartate transaminase; HOMA-IR, homeostasis model assessment of insulin resistance; STAT5, signal transducer and activator of transcription; TGF, transforming growth factor; α-SMA, α-smooth muscle actin. 1, respectively) . p values were ≤0.01 and 0.001 respectively. However, the levels of STAT5 were significantly lower in patients versus controls (9.69 ± 5.62 vs. 14.73 ± 6.52, p ≤ 0.001), and no significant difference was found in the lipid profile.
Results
The levels of TGF-β 1 and α-SMA increased progressively with advancing stages of hepatic fibrosis ( Table 3) . The TGF-β 1 values were 2,058.4 ± 973 in F1-F2 and 1,583.8 ± 853.88 in F3-F4 (p ≤ 0.04). The α-SMA values were 13.59 ± 5 in F1-F2 and 16.62 ± 7.3 in F3-F4 (p ≤ 0.05). However, fasting insulin, HOMA-IR, the lipid profile, and STAT5 were not significantly different.
TGF-β 1 levels showed a significant positive correlation with the stage of hepatic fibrosis (p ≤ 0.038); however STAT 5 and α-SMA were not significantly correlated (Table 4). Table 5 presents the association of the serum STAT 5 level and TGF-β 1 with some demographic, biochemical, metabolic factors in CHC patients. STAT5 levels showed a significant negative correlation with TGF-β 1 (r = -0.746 and p ≤ 0.001) and a weak positive correlation with HDL cholesterol (r = 0.236 and p ≤ 0.05). TGF-β 1 levels were positively correlated with serum triglyceride levels and negatively correlated with HDL cholesterol (r = 0.240 and -0.250, respectively, and p ≤ 0.04 and ≤ 0.05, respectively). α-SMA levels had a nonsignificant correlation. Figure 1 shows the receiver operating characteristic analysis for demonstration of the accuracy of indices and cut-off values for the studied serum biomarkers for predicting liver fibrosis according to the Fibroscan scoring system. The AUC for TGF-β 1 was 0.641 (p < 0.05), with a sensitivity of 58.6% and a specificity of 52.8% at a cut-off of 1,397. For α-SMA, the AUC was 0.629 (p < 0.07), with a sensitivity of 62.1% and a specificity of 52.8% at a cut-off of 14.1. The AUC for STAT5 was 0.526 (p < 0.7), with a sensitivity of 55% and a specificity of 52.8% at a cut-off 7.4.
Discussion
This study showed that STAT-5 levels were significantly lower while TGF-β 1 levels were significantly higher in CHC patients than in control subjects, with a negative correlation between them. TGF-β 1 levels showed a highly significant positive correlation with the stage of hepatic fibrosis. α-SMA levels were significantly higher Values are presented as means ± SD (range). STAT5, signal transducer and activator of transcription; TGF, transforming growth factor; α-SMA, α-smooth muscle actin; TG, triglycerides; HOMA-IR, homeostasis model assessment of insulin resistance. in patients than in controls and showed a significant progressive increase with advancing stages of hepatic fibrosis.
The mechanism of serum STAT5 reduction in patients with CHC is not clearly understood [18] . Animal studies showed that cytokine-induced activation of the JAK-STAT pathway plays a variety of important functions in liver pathophysiology. Experiments on knockout mice showed that the loss of STAT5 in hepatocytes resulted in elevated TGF-β 1 levels and enhanced the GH-induced STAT3 activity in the liver after chronic carbon tetrachloride treatment, suggesting that STAT5 inhibits liver fibrogenesis via the downregulation of TGF-β 1 and STAT3 [6, 19] . However, an acquired GH resistance in liver fibrosis, because of low GH receptor levels, has been previously reported [20, 21] . The reduction of STAT5 might also occur irrespectively of GH, because hepatocytes lose their hormonal response during early stages of fibrosis. The absence of STAT5 could lead to engagement of its receptors by other STAT members, especially STAT3 and STAT1, which in turn would result in their aberrant activation [5, 22] . STAT5 might reduce hepatic fibrosis through its counteractive effect on the TGF-β 1 as described in experimental studies [8, 19] . These possible mechanisms suggest how STAT5 might be an antagonist of fibrosis.
In this study, TGF-β 1 levels showed a significant increase in patients compared to controls, with a highly significant positive correlation with the stage of liver fibrosis. As activation of latent TGF-β 1 was reported to be the starting point of fibrogenesis, its levels might reflect the histologic stage [23, 24] , and some of the antifibrotic effects may be mediated by inhibition of profibrogenic TGF-β 1 [25] [26] [27] . Other studies have reported a significant elevation of TGF-β 1 in liver cirrhosis, with a moderate correlation of its levels with the grade of activity [28, 29] . TGF-β 1 plays a role in liver fibrosis through stimulation of the activation of HSC and the production of ECM as it may lead to cirrhosis through induction of hepatocyte apoptosis [13] .
In this study, the serum levels of α-SMA were significantly higher in CHC patients in compared to controls and their levels significantly increased with worsening of fibrosis, as with TGF-β1, but no significant correlation could be detected with serum STAT 5. Despite extensive experimental investigations on the effects STAT5 on hepatocytes, little is known about its possible effects on HSC. Moreover, the production of abnormal ECM and activated HSC may trigger the expression of α-SMA [30] .
Serum STAT5 levels in this study showed a weak positive correlation with HDL cholesterol; thus, a possible protective role of STAT5 against hepatic steatosis could be suggested. GH-STAT5 signaling may be involved in controlling the lipid metabolism in the liver, and thus the loss of STAT5 may induce hepatosteatosis [6] . Liver-specific STAT5 ablation in mice was shown to lead to the development of hepatosteatosis, glucose intolerance, and insulin resistance [6] .
The absence of any significant relation between STAT5 levels and glucose levels or IR in this study might be explained by the exclusion criteria of obese and diabetic subjects. Despite the exclusion of diabetic and obese patients, an interesting positive correlation was found between TGF-β 1 and serum triglyceride levels; there was also a negative correlation with HDL-c. Actually, hypertriglyceridemia and low HDL levels represent 2 important criteria of the metabolic syndrome. The hepatic fibrogenic response induced by TGF-β 1 could be directly inhibited in vitro by using an antihypertriglyceridemic agent, i.e., bezafibrate [31] . Herder et al. [32] reported an association between elevated serum concentrations of TGF-β 1 and the incidence of type 2 diabetes mellitus. In addition, TGF-β 1 has the potential to increase insulin resistance.
As liver fibrosis represents a complex process that triggers many cellular events and inflammatory cytokines, its exact mechanism is still a matter of debate [3, 4] . This may explain the low sensitivity and specificity of STAT5 in the prediction of liver fibrosis. However, this study suggests that STAT5 may play a significant role in hepatic fibrogenesis mostly through induction of TGF-β 1 and not through the activation of HSC. This study also suggests the therapeutic potential of the reduction of TGF-β 1 and the induction of STAT5 in hepatic fibrosis.
Despite being limited by the small number of patients, this study is suggestive of a novel role for STAT5 in developing liver fibrosis in CHC patients. Another limitation of this study is the difficulty of performing liver biopsies, as our national program for new antiviral therapy has stopped the use of liver biopsy as a diagnostic tool for eligibility for enrollment in the treatment program. Instead, we used Fibroscan for detection of the stage of hepatic fibrosis.
Conclusions
In Egyptian patients with HCV infection, STAT5, TGF-β 1 , and α-SMA are important contributing factors to fibrogenic activity. Reduced STAT5 in CHC patients may play a significant role in hepatic fibrogenesis through the induction of TGF-β 1 and not through the activation of HSC. Further research and more clarification through tissue expression of STAT5, TGF-β 1 , and α-SMA in CHC patients are indicated.
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